We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Ocular hypertension management in long-term treatments with intravitreal dexamethasone implants: a 3-year experience.
- Authors
Monsellato, R.; Trovato, E.; Turchetti, P.; Forestiere, M.; Pistone, A.; De Sio, S.; Accetta, L.; Pacella, F.
- Abstract
Purpose.A commonly recognized complication of intravitreal steroids is ocular hypertension (OHT).The aim of this study was to investigate the effectiveness of pharmacotherapy in controlling this side effect, even in patients receiving sequential injections. Methods.A total of 146 injections were performed on 78 patients over 3 years. 78 eyes were treated with 1 injection, 44 eyes were treated with 2 injections; 24 eyes were treated with 3 injections. The intravitreal corticosteroid used in this observational study is 0.7mg dexamethasone, commercially known as 0.7mg Ozurdex®. Results. Following the first injection, mean intraocular pressure (IOP) increased by 1,90 mmHg. Following the second injection, mean IOP increased by 0.23 mmHg. Following the third injection, there was no statistically significant change. Patients with IOP >= 21mmHg (7% of all participants) were started on topical pressure-lowering medications. Conclusion. Intravitreal dexamethasone implants increased IOP of variable degrees in different patients. However, secondary OHT was effectively controlled with pharmacotherapy alone. This allowed for continuation of dexamethasone therapy.
- Subjects
OCULAR hypertension; DEXAMETHASONE; DRUG therapy; PATIENTS; GLAUCOMA
- Publication
Clinica Terapeutica, 2020, Vol 171, Issue 1, pe11
- ISSN
0009-9074
- Publication type
Article
- DOI
10.7417/CT.2020.2182